drugset / Trial / NCT04794205

Acute Changes In Thermal Pain Response Following Single Oral Dose of Beta-Cary

NCT04794205

Phase 1/2 Withdrawn Hartford Hospital
RandomizedCrossoverQuadruple-blindOther

Summary

Beta-Caryophyllene is an essential oil and cannabis plant derivative also found in edible herbs. It has shown promise as a potential analgesic in preclinical trials. However, there are no human studies characterizing pharmacokinetics of BCP in humans. Therefore, it is of great importance to determine the pharmacokinetics of BCP in humans so that appropriate dosing can be developed for analgesia. This pharmacokinetic work will lay the groundwork for subsequent experiments testing the neural mechanism of BCP on pain.

Timeline

Start
2021-09
Primary completion
2022-04
Completion
2022-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Beta-Caryophyllene Small molecule 5 mg Oral
Subject Beta-Caryophyllene Small molecule 30 mg Oral
Subject Beta-Caryophyllene Small molecule 150 mg Oral

Indications

No indication recorded.